MD Anderson’s Therapeutics Discovery division, Orionis Biosciences launch Project Helios to advance novel small-molecule cancer medicines

HOUSTON, BOSTON and GHENT, Belgium – The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division and Orionis Biosciences today announced the launch of Project Helios, a research collaboration designed to unlock new drug development opportunities through genome-scale mapping of drug-target interactions. Combining Orionis’ unique high-throughput drug discovery technologies with the Therapeutics Discovery division’s…

Details

Covid-19 risk increases with airborne pollen

In the spring of 2020, the outbreak of the coronavirus pandemic appeared to coincide with the tree pollen season in the northern hemisphere. These observations prompted an international team of researchers to conduct an extensive investigation: The scientists wanted to know whether there is a demonstrable link between airborne pollen concentrations and SARS-CoV-2 infection rates.…

Details

Lower dose, less toxic radiopharmaceutical produces better outcomes

Neuroendocrine tumours are cancers that begin in specialised cells called neuroendocrine cells. These cells have traits similar to those of nerve cells and hormone-producing cells. Neuroendocrine tumours, while rare, can occur anywhere in the body. Most affect the cardiothoracic region, eg lungs, appendix, small intestine, pancreas as well as the rectum. There are many types…

Details